CADTH Canadian Drug Expert Committee recommendation: Tapentadol hydrochloride (Nucynta extended-release -- Paladin Labs Inc.) indication : management of pain severe enough to require daily, continuous, long-term opioid treatment, and that is opioid responsive; and for which alternative treatment options are inadequate
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, October 2018
|
Edition: | Version: Final |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Physical Description: | 1 PDF file (9 pages) |
---|